We are pleased to announce the publication of a new article introducing CardioPharmaGENET in the prestigious European Heart Journal, published on behalf of the European Society of Cardiology (ESC). The CardioPulse article “CardioPharmaGENET: A New European Network for Pharmacogenomics-Driven Cardiovascular Care,” authored by Adna Ašić, Svetlana Frolova, and Yvan Devaux, was published in October 2026,…
CardioPharmaGENET
On 1–2 October 2026, Sarajevo hosted the 1st Extended Core Group Meeting of COST Action CardioPharmaGENET (CA24165) at the International University of Sarajevo (IUS), bringing together members of the Action to review achievements from the first Grant Period, define priorities for the next implementation phase, and strengthen scientific collaboration within the international CardioPharmaGENET network. The…
The Memorandum of Understanding (MoU) of CardioPharmaGENET (CA24165) has been published in the Journal of Molecular and Cellular Cardiology Plus. The publication presents the COST Action network and its mission to advance cardiovascular pharmacogenomics and precision medicine through multidisciplinary collaboration, knowledge exchange, capacity building, and translation of research into clinical practice. Read the full publication:…
On 10 September 2026, COST Actions CardioPharmaGENET (CA24165) and INFLAMomx (CA24166) successfully organised the joint webinar “Precision Medicine at the Crossroads of Cardiovascular Disease and Inflammation.” The online event brought together 85 participants for an interdisciplinary discussion on the connections between cardiovascular disease, chronic inflammation, and precision medicine. Moderated by Dr. Yvan Devaux, the webinar…
